Legend Biotech Corporation (LEGN)
NASDAQ: LEGN · Real-Time Price · USD
28.13
+0.32 (1.15%)
At close: Dec 5, 2025, 4:00 PM EST
28.11
-0.02 (-0.07%)
After-hours: Dec 5, 2025, 7:57 PM EST
Legend Biotech Stock Forecast
Stock Price Forecast
The 12 analysts with 12-month price forecasts for Legend Biotech stock have an average target of 72.92, with a low estimate of 54 and a high estimate of 90. The average target predicts an increase of 159.23% from the current stock price of 28.13.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Legend Biotech stock from 13 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 6 | 7 | 7 | 7 | 8 | 8 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 12 | 12 | 12 | 13 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Maintains $94 → $90 | Buy | Maintains | $94 → $90 | +219.94% | Nov 13, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $75 → $74 | Buy | Maintains | $75 → $74 | +163.06% | Nov 13, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $66 → $75 | Buy | Maintains | $66 → $75 | +166.62% | Nov 13, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $75 → $60 | Strong Buy | Maintains | $75 → $60 | +113.30% | Oct 17, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $78 → $76 | Buy | Maintains | $78 → $76 | +170.17% | Oct 9, 2025 |
Financial Forecast
Revenue This Year
1.06B
from 627.24M
Increased by 68.83%
Revenue Next Year
1.60B
from 1.06B
Increased by 51.27%
EPS This Year
-0.95
from -0.97
EPS Next Year
0.47
from -0.95
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 1.1B | 2.0B | ||||
| Avg | 1.1B | 1.6B | ||||
| Low | 991.6M | 1.3B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 82.5% | 89.7% | ||||
| Avg | 68.8% | 51.3% | ||||
| Low | 58.1% | 27.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.70 | 1.04 | |||
| Avg | -0.95 | 0.47 | |||
| Low | -1.56 | 0.16 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.